Enhancing the Inhibition of Breast Cancer Growth Through Synergistic Modulation of the Tumor Microenvironment Using Combined Nano-Delivery Systems
DOI: https://doi.org/10.2147/ijn.s460874
IF: 7.033
2024-06-04
International Journal of Nanomedicine
Abstract:Jingliang Wu, 1, &ast Qiao Lu, 1, 2, &ast Jialin Zhao, 3, &ast Wendi Wu, 3 Zhihua Wang, 1 Guohua Yu, 4 Guixiang Tian, 2 Zhiqin Gao, 2 Qing Wang 5 1 School of Medicine, Weifang University of Science and Technology, Weifang, 262700, People's Republic of China; 2 School of Life Science and Technology, Shandong Second Medical University, Weifang, 261053, People's Republic of China; 3 School of Clinical Medicine, Shandong Second Medical University, Weifang, 261053, People's Republic of China; 4 Department of Oncology, Weifang People's Hospital, Weifang, 261000, People's Republic of China; 5 Department of Stomatology, Weifang People's Hospital, Weifang, 261000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Qing Wang, Department of Stomatology, Weifang People's Hospital, Weifang, 261000, People's Republic of China, Tel +86 158 6362 6389, Email Purpose: Breast cancer is a prevalent malignancy among women worldwide, and malignancy is closely linked to the tumor microenvironment (TME). Here, we prepared mixed nano-sized formulations composed of pH-sensitive liposomes (Ber/Ru486@CLPs) and small-sized nano-micelles (Dox@CLGs). These liposomes and nano-micelles were modified by chondroitin sulfate (CS) to selectively target breast cancer cells. Methods: Ber/Ru486@CLPs and Dox@CLGs were prepared by thin-film dispersion and ethanol injection, respectively. To mimic actual TME, the in vitro "condition medium of fibroblasts + MCF-7" cell model and in vivo " 4T1/NIH-3T3" co-implantation mice model were established to evaluate the anti-tumor effect of drugs. Results: The physicochemical properties showed that Dox@CLGs and Ber/Ru486@CLPs were 28 nm and 100 nm in particle size, respectively. In vitro experiments showed that the mixed formulations significantly improved drug uptake and inhibited cell proliferation and migration. The in vivo anti-tumor studies further confirmed the enhanced anti-tumor capabilities of Dox@CLGs + Ber/Ru486@CLPs, including smaller tumor volumes, weak collagen deposition, and low expression levels of α-SMA and CD31 proteins, leading to a superior anti-tumor effect. Conclusion: In brief, this combination therapy based on Dox@CLGs and Ber/Ru486@CLPs could effectively inhibit tumor development, which provides a promising approach for the treatment of breast cancer. Keywords: drug delivery, cancer-associated fibroblasts, glucocorticoids, combination therapy Breast cancer is one of the most prevalent malignant tumors worldwide, ranking as the second leading cause of cancer-related fatalities among female subjects. 1,2 Elevated rates of cancer progression, metastasis, and chemotherapy resistance are pivotal factors associated with the diminished survival of breast cancer patients. 3,4 Research has proven that the tumor microenvironment (TME) significantly contributes to these outcomes. 5,6 TME consists of the extracellular matrix (ECM), cytokines and various tumor stromal cells, including fibroblasts, immune cells, inflammatory cells and endothelial cells. 7 The combined strategy of TME-regulating the pro-apoptotic activities has attracted more and more attention in anti-tumor therapy. Cancer-associated fibroblasts (CAFs), as the most abundant stromal cells in TME, are activated from normal fibroblasts, 8 and play an important role in fostering tumor growth. 9,10 Researchers have shown that CAFs could induce epithelial-mesenchymal transitions (EMT) of tumor cells by secreting TGF-β, 11 ultimately leading to tumor metastasis. 12 In addition, CAFs are directly implicated in immunosuppression and drug resistance. They possess the ability to reprogram tumor cell metabolism, and protecting them from apoptosis triggered through treatment. 13–17 Due to the specific distribution and important role of CAFs within tumors, they are increasingly becoming a therapeutic target for the treatment of breast cancer. Berberine (Ber), an isoquinoline quaternary alkaloid extracted from rhizoma coptidis, cortex phellodendri and other medicinal plants, has been proven to possess multiple pharmacological characteristics, including anti-inflammation, antioxidative, anti-diabetic and antitumor activities. Recent research showed that Ber could inhibit CAFs activation, 18,19 collagen deposition, and TGF-β secretion, 20 resulting in the effective suppression of cancer cell metastasis. Hence, the combination of Ber and chemotherapy might be an effective approach to inhibit tumor development. F -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology